The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for July 2015.
Mesenchymal Stem Cell News Round-Up for July 2015
IL-17 Supercharges Stem Cell Growth
[July 10, 2015] Researchers have shown that adding the cytokine IL-17 to the culture medium helps stem cells grow faster and stronger. The study, published in Stem Cells, is expected to eventually lead to new treatments for transplant patients.
MiMedx Allografts Stimulate Cellular Proliferation And Migration In A Variety Of Adult Stem Cells
[July 15, 2015] This recently published study was established to evaluate the impact of MiMedx PURION® Processed dHACM on various reparative stem cells, including MSCs, adipose derived stem cells (ADSCs), and HSCs using in vitro cell closure and proliferation models, and the measurement of changes in the growth factor/cytokine secretion profile for each cell type to further elucidate the mechanisms by which dHACM may enhance healing.
Congestive Heart Failure Phase 2 Trial Results
[July 15, 2015] Mesoblast Limited today announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure (CHF) have been published in the latest edition of Circulation Research. Patients with advanced heart failure have a poor long-term prognosis and few therapeutic options. Mesoblast’s proprietary Mesenchymal Precursor Cells (MPCs) may offer a promising alternative because of their ability to induce heart muscle repair, stimulate new blood vessel growth, decrease cell death and reduce scar formation.
Stem cell transplant alleviates symptoms in lupus animal models
[July 14, 2015] Systemic lupus erythematosus (SLE) is an autoimmune disease that produces autoantibodies and subsequent immune reactions that can lead to a variety of symptoms, including inflammation of the kidneys, or nephritis. When researchers transplanted mesenchymal stem cells (MSCs) derived from human bone marrow into mice modeled with SLE, they found that inflammation was reduced and nephritis “attenuated.” They suggested that their study revealed a “novel mechanism” by which the MSCs can regulate the progression of autoimmune diseases such as SLE.
Researchers at Penn Develop Scar-like Culture Systems to Understand and Treat Fibrosis
[July 15, 2015] A study from the University of Pennsylvania has developed a ”‘scar in a dish” in order to uncover mechanisms that cells use to sense this fibrous tissue. The system will be helpful for understanding the roots of the scars’ stiffness, and ultimately lead to treatments that would help revert the tissue to its normal consistency.
Stem Cells Programmed to Survive Within Harsh Post MI Environments
[June 23, 2015] While stem cells for healing diseased cardiac tissue have shown some promise, their inability to wow us may be due to the low rate of survival of these cells once they are inside the myocardium, especially if it’s scarred by the previous infarction. In addition to a low perfusion environment, unbalance of signalling molecules inside the scarred heart is partially responsible for early apoptosis of stem cells.
A microRNA molecule called miR-133a has been noted to be in abnormally low quantities in patients following a heart attack. Researchers at Ohio State University thought that if they prime stem cells with high levels of miR-133a, as though they are in a healthy environment, once implanted into a diseased area they won’t be as susceptible to low levels of miR-133a that’s telling them it’s time to begin apostosis.
To learn more about opportunities for commercializing MSCs, view the global strategic report “Mesenchymal Stem Cells – Advances & Applications” now.
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
BioInformant is the only research firm that has served the cord blood sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM).